ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates and financial results for the third […]
Other News
Catasys Appoints Three Healthcare Executives to Board of Directors
LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced the appointment of Edward Zecchini, Sharon Gabrielson, and Diane Seloff to its Board of Directors. Messrs. Rick Anderson and Dave Smith have stepped down as directors to accommodate the new Board members. […]
4TECH Inc. Reports First U.S. Clinical Implantations of Its TriCinch™ Coil Tricuspid Valve Repair System
GALWAY, Ireland–(BUSINESS WIRE)–4TECH Inc., a leader in the field of transcatheter tricuspid valve repair, initiated its U.S. Early Feasibility Study, following receipt of approval from the U.S. Food and Drug Administration (FDA), with the successful first two implantations of the TriCinch™ Coil System at Piedmont Heart Hospital, Atlanta, Georgia, by Dr. Christopher Meduri, Dr. Vivek […]
Cardiac Insight, Inc. Partners with VivoSense® (Vivonoetics, Inc.) to Expand the Use of Its Wearable Cardiac Sensors in Regulated Pharmaceutical Clinical Trials and Other Healthcare Research Applications
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, announced today it has partnered with VivoSense®, a leader in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will […]
REVA Announces Commercial Launch of the Fantom Encore Bioresorbable Scaffold
SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the commercial launch of the Fantom Encore bioresorbable scaffold (“BRS”) and the first implant of Fantom Encore in the FANTOM Post Market Trial. […]
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018. Second quarter fiscal […]
Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios
RARITAN, N.J., Nov. 1, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 46 company-sponsored and more than 37 investigator-led abstracts will be presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, CA on December 1-4. Highlights include eight company-sponsored oral presentations, including data for the Bruton’s tyrosine kinase (BTK) […]
CryoLife Reports Third Quarter 2018 Results
ATLANTA, Oct. 31, 2018 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018. Third Quarter and Recent Business Highlights: Total revenues increased 47 percent to $64.6 million in the third quarter of 2018 compared to the […]
Osprey Medical Announces Capital Raising of US$14.5M to Accelerate US and International Growth
MINNEAPOLIS–(BUSINESS WIRE)–Minnesota-based Osprey Medical Inc. (ASX:OSP) (Osprey or Company) today announces that it has entered into an agreement with Allan Gray, a leading investment management firm, to subscribe for approximately 64.5m CHESS Depositary Interests (CDIs) in the Company (representing approximately 32.3m shares of common stock) through the Australian Securities Exchange (ASX) at […]
Teleflex Reports Third Quarter 2018 Results
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2018. Third quarter 2018 net revenues were $609.7 million, an increase of 14.0% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, third quarter 2018 […]



